Cargando…
Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG(1–4), IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies
BACKGROUND: The quantitative suspension array technology (qSAT) is a useful platform for malaria immune marker discovery. However, a major challenge for large sero-epidemiological and malaria vaccine studies is the comparability across laboratories, which requires the access to standardized control...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984756/ https://www.ncbi.nlm.nih.gov/pubmed/29859096 http://dx.doi.org/10.1186/s12936-018-2369-3 |
_version_ | 1783328657386766336 |
---|---|
author | Ubillos, Itziar Jiménez, Alfons Vidal, Marta Bowyer, Paul W. Gaur, Deepak Dutta, Sheetij Gamain, Benoit Coppel, Ross Chauhan, Virander Lanar, David Chitnis, Chetan Angov, Evelina Beeson, James Cavanagh, David Campo, Joseph J. Aguilar, Ruth Dobaño, Carlota |
author_facet | Ubillos, Itziar Jiménez, Alfons Vidal, Marta Bowyer, Paul W. Gaur, Deepak Dutta, Sheetij Gamain, Benoit Coppel, Ross Chauhan, Virander Lanar, David Chitnis, Chetan Angov, Evelina Beeson, James Cavanagh, David Campo, Joseph J. Aguilar, Ruth Dobaño, Carlota |
author_sort | Ubillos, Itziar |
collection | PubMed |
description | BACKGROUND: The quantitative suspension array technology (qSAT) is a useful platform for malaria immune marker discovery. However, a major challenge for large sero-epidemiological and malaria vaccine studies is the comparability across laboratories, which requires the access to standardized control reagents for assay optimization, to monitor performance and improve reproducibility. Here, the Plasmodium falciparum antibody reactivities of the newly available WHO reference reagent for anti-malaria human plasma (10/198) and of additional customized positive controls were examined with seven in-house qSAT multiplex assays measuring IgG, IgG(1–4) subclasses, IgM and IgE against a panel of 40 antigens. The different positive controls were tested at different incubation times and temperatures (4 °C overnight, 37 °C 2 h, room temperature 1 h) to select the optimal conditions. RESULTS: Overall, the WHO reference reagent had low IgG2, IgG4, IgM and IgE, and also low anti-CSP antibody levels, thus this reagent was enriched with plasmas from RTS,S-vaccinated volunteers to be used as standard for CSP-based vaccine studies. For the IgM assay, another customized plasma pool prepared with samples from malaria primo-infected adults with adequate IgM levels proved to be more adequate as a positive control. The range and magnitude of IgG and IgG(1–4) responses were highest when the WHO reference reagent was incubated with antigen-coupled beads at 4 °C overnight. IgG levels measured in the negative control did not vary between incubations at 37 °C 2 h and 4 °C overnight, indicating no difference in unspecific binding. CONCLUSIONS: With this study, the immunogenicity profile of the WHO reference reagent, including seven immunoglobulin isotypes and subclasses, and more P. falciparum antigens, also those included in the leading RTS,S malaria vaccine, was better characterized. Overall, incubation of samples at 4 °C overnight rendered the best performance for antibody measurements against the antigens tested. Although the WHO reference reagent performed well to measure IgG to the majority of the common P. falciparum blood stage antigens tested, customized pools may need to be used as positive controls depending on the antigens (e.g. pre-erythrocytic proteins of low natural immunogenicity) and isotypes/subclasses (e.g. IgM) under study. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12936-018-2369-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5984756 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59847562018-06-07 Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG(1–4), IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies Ubillos, Itziar Jiménez, Alfons Vidal, Marta Bowyer, Paul W. Gaur, Deepak Dutta, Sheetij Gamain, Benoit Coppel, Ross Chauhan, Virander Lanar, David Chitnis, Chetan Angov, Evelina Beeson, James Cavanagh, David Campo, Joseph J. Aguilar, Ruth Dobaño, Carlota Malar J Methodology BACKGROUND: The quantitative suspension array technology (qSAT) is a useful platform for malaria immune marker discovery. However, a major challenge for large sero-epidemiological and malaria vaccine studies is the comparability across laboratories, which requires the access to standardized control reagents for assay optimization, to monitor performance and improve reproducibility. Here, the Plasmodium falciparum antibody reactivities of the newly available WHO reference reagent for anti-malaria human plasma (10/198) and of additional customized positive controls were examined with seven in-house qSAT multiplex assays measuring IgG, IgG(1–4) subclasses, IgM and IgE against a panel of 40 antigens. The different positive controls were tested at different incubation times and temperatures (4 °C overnight, 37 °C 2 h, room temperature 1 h) to select the optimal conditions. RESULTS: Overall, the WHO reference reagent had low IgG2, IgG4, IgM and IgE, and also low anti-CSP antibody levels, thus this reagent was enriched with plasmas from RTS,S-vaccinated volunteers to be used as standard for CSP-based vaccine studies. For the IgM assay, another customized plasma pool prepared with samples from malaria primo-infected adults with adequate IgM levels proved to be more adequate as a positive control. The range and magnitude of IgG and IgG(1–4) responses were highest when the WHO reference reagent was incubated with antigen-coupled beads at 4 °C overnight. IgG levels measured in the negative control did not vary between incubations at 37 °C 2 h and 4 °C overnight, indicating no difference in unspecific binding. CONCLUSIONS: With this study, the immunogenicity profile of the WHO reference reagent, including seven immunoglobulin isotypes and subclasses, and more P. falciparum antigens, also those included in the leading RTS,S malaria vaccine, was better characterized. Overall, incubation of samples at 4 °C overnight rendered the best performance for antibody measurements against the antigens tested. Although the WHO reference reagent performed well to measure IgG to the majority of the common P. falciparum blood stage antigens tested, customized pools may need to be used as positive controls depending on the antigens (e.g. pre-erythrocytic proteins of low natural immunogenicity) and isotypes/subclasses (e.g. IgM) under study. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12936-018-2369-3) contains supplementary material, which is available to authorized users. BioMed Central 2018-06-01 /pmc/articles/PMC5984756/ /pubmed/29859096 http://dx.doi.org/10.1186/s12936-018-2369-3 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Methodology Ubillos, Itziar Jiménez, Alfons Vidal, Marta Bowyer, Paul W. Gaur, Deepak Dutta, Sheetij Gamain, Benoit Coppel, Ross Chauhan, Virander Lanar, David Chitnis, Chetan Angov, Evelina Beeson, James Cavanagh, David Campo, Joseph J. Aguilar, Ruth Dobaño, Carlota Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG(1–4), IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies |
title | Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG(1–4), IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies |
title_full | Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG(1–4), IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies |
title_fullStr | Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG(1–4), IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies |
title_full_unstemmed | Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG(1–4), IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies |
title_short | Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG(1–4), IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies |
title_sort | optimization of incubation conditions of plasmodium falciparum antibody multiplex assays to measure igg, igg(1–4), igm and ige using standard and customized reference pools for sero-epidemiological and vaccine studies |
topic | Methodology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984756/ https://www.ncbi.nlm.nih.gov/pubmed/29859096 http://dx.doi.org/10.1186/s12936-018-2369-3 |
work_keys_str_mv | AT ubillositziar optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies AT jimenezalfons optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies AT vidalmarta optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies AT bowyerpaulw optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies AT gaurdeepak optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies AT duttasheetij optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies AT gamainbenoit optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies AT coppelross optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies AT chauhanvirander optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies AT lanardavid optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies AT chitnischetan optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies AT angovevelina optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies AT beesonjames optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies AT cavanaghdavid optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies AT campojosephj optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies AT aguilarruth optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies AT dobanocarlota optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies |